The role of granulocyte colony-stimulating factors in the prevention of neutropenia and febrile neutropenia – the current state of knowledge
Journal Title: OncoReview - Year 2017, Vol 7, Issue 1
Abstract
Granulocyte colony-stimulating factors, introduced in the 1990s to prevent neutropenic fever, improve patients’ prognosis after myelotoxic chemotherapy. G-CSFs accelerate bone marrow recovery, shortening the duration of neutropenia and reducing its intensity as well as the risk of febrile neutropenia. There are short- and long-acting G-CSFs available these days. This paper is a review of the efficacy, toxicity and indications for short- and long-acting G-CSFs as indicated in the most recent studies.
Authors and Affiliations
Marta A. Sobas, Tomasz Wróbel
Keywords
Related Articles
- EP ID EP187335
- DOI -
- Views 222
- Downloads 0
Myeloma and amyloid
Late relapse of chronic myeloid leukemia after allogeneic stem cell tranplan
Chronic myeloid leukemia now is a disease which in the most cases is well manageable with tyrosine kinase inhibitors treatment. Still however the only potentially curable therapeutic approach is for chronic myeloid leuke...
Cardiooncological balance in a 75-year-old male with a hepatocellular carcinoma CS IV and a congestive heart failure NYHA III „de novo”
The case reports about a 75-years-old man without a previous medical history, in whom a heart failure NYHA III de novo was diagnosed together with persistent atrial fibrillation and hepatocellular carcinoma in clinical s...
Non-pegylated liposomal doxorubicin plus capecitabine as first-line treatment in metastatic breast cancer
Purpose: To determine the toxicity and efficacy profile of non-pegylated doxorubicin in combination with capecitabine administered according to LipAX regimen.
Radiotherapy in patients with cardiac implantable electronic devices – clinical experience
The number of patients with cardiac implantable electronic devices (CIEDs) constantly increases and due to growing incidence of cancer, many of them will require an anticancer treatment. At least a half of patients treat...